Why ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Up 15.89%
As of Friday, August 21, ARS Pharmaceuticals, Inc.’s SPRY share price has surged by 15.89%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Commentary & Analysis
Is ARS Pharmaceuticals, Inc. (SPRY) Overvalued?
We dive into why ARS Pharmaceuticals, Inc. (SPRY) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Jenna Brashear
Why ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Down 8.36%
As of Friday, August 14, ARS Pharmaceuticals, Inc.’s SPRY share price has dipped by 8.36%, which has investors questioning if this is right time to buy.Rosalio Madrigal
What You Need to Know About ARS Pharmaceuticals, Inc.'s Q3 Earnings
ARS Pharmaceuticals, Inc.'s fiscal Q3 earnings report was released on Thursday, August 13. Let's dive in to see if (SPRY) missed or beat analyst's expectations.Jenna Brashear
Why ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Up 9.01%
As of Friday, August 07, ARS Pharmaceuticals, Inc.’s SPRY share price has surged by 9.01%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | SPRY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $547.5 | $286.3 | 38% |
|
| Shares Out (Mil) | 99.3 | 54.2 | 62% |
|
| Institutional Ownership | 90.6% | 92.8% | 59% |
|
| Float (Mil) | 48.0 | 39.7 | 46% |
|
| Beta | 0.97 | 0.94 | 59% |
|
| Avg Daily Volume (000s) | 2,095 | 534 | 82% |
|
| Price Change (52-week) |
(60.1%) | 58.7% | 11% |
|
| Growth | SPRY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 36.5% | 13.6% | 92% |
|
| Net Income (5yr) | (174.5%) | (10.1%) | 0% |
|
| EPS (5yr) | (101.0%) | 16.0% | 1 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.5%) | (15.6%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.303) | ($1.840) | ($0.890) | |
| Month Ago EPS | ($0.270) | ($1.720) | ($0.943) | |
| # Rev Up | 0 | 0 | 2 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.330) | ($1.760) | ($0.953) | |
| Year/Year Chg | (51.8%) | 5.7% | (93.1%) | |
| Financials | SPRY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $117 | $37 | 28% |
|
| Net Income (TTM) (Mil) | ($215) | ($43) | 6% |
|
| EPS (TTM) | ($2.174) | ($1.400) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($196) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($43) | $2 | 20% |
|
| Long-Term Debt (Q1) (Mil) | $172 | $4 | 48% |
|
| Enterprise Value (Q1) (Mil) | $590 | $160 | 36% |
|
| Valuation | SPRY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 42.35 | 2.77 | 98% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | SPRY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 58.3% | 64.2% | 71% |
|
| Net Margin | (184.2%) | (75.9%) | 5% |
|
| ROA | (76.5%) | (47.3%) | 8% |
|
| ROE | (210.3%) | (55.0%) | 4% |
|
| Liabilities to Assets | 95.0% | 29.6% | 92% |
|
| F-Score | 1 | 2 | 1% |
|
ARS Pharmaceuticals, Inc. did not pass any screens on 8/20/2026.
